MX2017005663A - Tetrahidropiranos sustituidos y metodo de uso. - Google Patents

Tetrahidropiranos sustituidos y metodo de uso.

Info

Publication number
MX2017005663A
MX2017005663A MX2017005663A MX2017005663A MX2017005663A MX 2017005663 A MX2017005663 A MX 2017005663A MX 2017005663 A MX2017005663 A MX 2017005663A MX 2017005663 A MX2017005663 A MX 2017005663A MX 2017005663 A MX2017005663 A MX 2017005663A
Authority
MX
Mexico
Prior art keywords
compounds
formula
methods
substituted tetrahydropyrans
compositions
Prior art date
Application number
MX2017005663A
Other languages
English (en)
Inventor
R Kym Philip
B Searle Xenia
Liu Bo
C Yeung Ming
WANG Xueqinq
Original Assignee
Abbvie Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Sarl filed Critical Abbvie Sarl
Publication of MX2017005663A publication Critical patent/MX2017005663A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de la fórmula (I): (ver Fórmula) y las sales farmacéuticamente aceptables o las formas radiomarcadas de los mismos, en donde R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 y m son como se definen en la memoria descriptiva, son útiles en el tratamiento de las afecciones o los trastornos que sean prevenidos o mitigados por la proteína reguladora de la conductancia transmembrana de la fibrosis quística (CFTR). Se describen los métodos para la elaboración de los compuestos. También se describen composiciones farmacéuticas de los compuestos de la fórmula (I) y los métodos para utilizar estos compuestos y composiciones.
MX2017005663A 2014-10-31 2015-10-29 Tetrahidropiranos sustituidos y metodo de uso. MX2017005663A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462073586P 2014-10-31 2014-10-31
PCT/US2015/058043 WO2016069891A1 (en) 2014-10-31 2015-10-29 Substituted tetrahydropyrans and method of use

Publications (1)

Publication Number Publication Date
MX2017005663A true MX2017005663A (es) 2018-03-01

Family

ID=55851906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005663A MX2017005663A (es) 2014-10-31 2015-10-29 Tetrahidropiranos sustituidos y metodo de uso.

Country Status (10)

Country Link
US (1) US9567322B2 (es)
EP (1) EP3212184B1 (es)
JP (1) JP6615213B2 (es)
CN (1) CN107427490A (es)
AU (1) AU2015339196A1 (es)
BR (1) BR112017009194A2 (es)
CA (1) CA2966023A1 (es)
MX (1) MX2017005663A (es)
TW (1) TW201625599A (es)
WO (1) WO2016069891A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2608474T3 (es) 2010-04-22 2017-04-11 Vertex Pharmaceuticals Incorporated Proceso de producción de compuestos indol cycloalkylcarboxamido
ES2885181T3 (es) 2014-04-15 2021-12-13 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
US9840513B2 (en) * 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
RU2724345C2 (ru) 2015-10-09 2020-06-23 Галапагос Нв N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
AU2016333855A1 (en) 2015-10-09 2018-04-26 AbbVie S.à.r.l. Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use
US10130622B2 (en) 2015-10-09 2018-11-20 Abbvie S.Á.R.L. Compounds for treatment of cystic fibrosis
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
EP3558982A1 (en) 2016-12-20 2019-10-30 AbbVie S.À.R.L. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
CN110483457A (zh) * 2018-05-14 2019-11-22 上海迈法生物科技有限公司 4-氨基四氢吡喃的一锅法合成工艺
EP3747882A1 (en) 2019-06-03 2020-12-09 AbbVie Overseas S.à r.l. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
TW202115014A (zh) 2019-07-12 2021-04-16 美商奧佛麥德公司 用於治療囊腫纖維化之化合物
EP4058434A1 (en) 2019-11-12 2022-09-21 Genzyme Corporation 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
WO2022150173A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2022150174A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06004005A (es) * 2003-10-08 2006-06-28 Vertex Pharma Moduladores de transportadores con casete de union con atp.
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
LT2502911T (lt) 2004-06-24 2017-09-11 Vertex Pharmaceuticals Incorporated Atp surišančios kasetės transporterių moduliatoriai
WO2008147952A1 (en) 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
JP5637859B2 (ja) 2007-12-13 2014-12-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
WO2009084034A2 (en) * 2007-12-18 2009-07-09 Glenmark Pharmaceuticals, S. A. Chromane derivatives as trpv3 modulators
EP2271621B1 (en) * 2008-03-31 2013-11-20 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as cftr modulators
CN102123987A (zh) 2008-07-28 2011-07-13 吉里德科学公司 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物
PT2358680E (pt) 2008-10-23 2013-05-14 Vertex Pharma Formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2- (trifluorometil)fenil)-4-oxo- 5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida
EP2382197B1 (en) 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
HRP20160682T1 (hr) 2010-04-07 2016-07-29 Vertex Pharmaceuticals Incorporated Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
EP2968323A4 (en) 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
EP2968285A4 (en) 2013-03-13 2016-12-21 Flatley Discovery Lab COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015138934A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity

Also Published As

Publication number Publication date
US20160122331A1 (en) 2016-05-05
TW201625599A (zh) 2016-07-16
EP3212184B1 (en) 2020-04-01
AU2015339196A1 (en) 2017-05-11
WO2016069891A1 (en) 2016-05-06
EP3212184A4 (en) 2018-07-04
CN107427490A (zh) 2017-12-01
BR112017009194A2 (pt) 2017-12-26
JP2017533277A (ja) 2017-11-09
EP3212184A1 (en) 2017-09-06
US9567322B2 (en) 2017-02-14
JP6615213B2 (ja) 2019-12-04
CA2966023A1 (en) 2016-05-06

Similar Documents

Publication Publication Date Title
MX2017005663A (es) Tetrahidropiranos sustituidos y metodo de uso.
GEP20247634B (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
MX2016010056A (es) 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
GEAP202115057A (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
SG10201902963PA (en) Modulators of cystic fibrosis transmembrane conductance regulator
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
MY190429A (en) Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
NZ750187A (en) Pyridone amides as modulators of sodium channels
MY193728A (en) Muscarinic receptor agonists
MX2015009270A (es) Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
TW201613864A (en) Novel compounds
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
MX2016009581A (es) Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso.
WO2017177004A8 (en) Tertiary amides and method of use
MD20170011A2 (ro) Compuşi imidazopiridazinici
MX2017002775A (es) Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b.
PH12017500595B1 (en) Aldosterone synthase inhibitors
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
MY193041A (en) Novel fused imidazobenzothiazole compounds
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора
PH12017501134A1 (en) Fumagillol derivatives